menu
    • menu
    [{"orgOrder":0,"company":"Orbus Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Eflornithine Hydrochloride","moa":"||ODC","graph1":"Oncology","graph2":"Phase III","graph3":"Orbus Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Orbus Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Orbus Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Orbus Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Eflornithine Hydrochloride","moa":"||ODC","graph1":"Oncology","graph2":"Phase III","graph3":"Orbus Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Orbus Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Orbus Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Orbus Therapeutics","sponsor":"Longitude Capital","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Series A Financing","leadProduct":"Eflornithine Hydrochloride","moa":"||ODC","graph1":"Oncology","graph2":"Phase III","graph3":"Orbus Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Orbus Therapeutics \/ Longitude Capital","highestDevelopmentStatusID":"10","companyTruncated":"Orbus Therapeutics \/ Longitude Capital"},{"orgOrder":0,"company":"Biodexa Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Panobinostat lactate","moa":"||HDAC","graph1":"Oncology","graph2":"Phase I","graph3":"Biodexa Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intratumoral Infusion","sponsorNew":"Biodexa Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Biodexa Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Midatech Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Panobinostat lactate","moa":"||HDAC","graph1":"Oncology","graph2":"Phase I","graph3":"Midatech Pharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intratumoral Infusion","sponsorNew":"Midatech Pharma \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Midatech Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Philogen","sponsor":"University Hospital Z\u00fcrich","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"ITALY","productType":"Protein","year":"2023","type":"Inapplicable","leadProduct":"Fibromun","moa":"||Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Philogen","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Philogen \/ University Hospital Z\u00fcrich","highestDevelopmentStatusID":"7","companyTruncated":"Philogen \/ University Hospital Z\u00fcrich"},{"orgOrder":0,"company":"Orbus Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Eflornithine Hydrochloride","moa":"||ODC","graph1":"Oncology","graph2":"Phase III","graph3":"Orbus Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Solution","sponsorNew":"Orbus Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Orbus Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Orbus Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Eflornithine Hydrochloride","moa":"||ODC","graph1":"Oncology","graph2":"Phase III","graph3":"Orbus Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Orbus Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Orbus Therapeutics \/ Inapplicable"}]

    Find Clinical Drug Pipeline Developments & Deals for Lomustine

    Menu

    Lomustine

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    FINISHED DOSAGE FORMULATIONS

    RELATED EXCIPIENT COMPANIES

    EXCIPIENTS BY APPLICATIONS

    DIGITAL CONTENT

    MARKET PLACE

    REF. STANDARDS & IMPURITIES

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Orbus Therapeutics

                            U.S.A arrow
                            AACR Annual meeting
                            Not Confirmed

                            Orbus Therapeutics

                            U.S.A arrow
                            AACR Annual meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Eflornithine Hydrochloride,Lomustine

                            Therapeutic Area : Oncology

                            Study Phase : Phase III

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Eflornithine & Lomustine Combination Shows Survival Benefit in Astrocytoma IDH Mutant

                            Details : A combination of an ODC inhibitor, eflornithine and cancer DNA inhibitor lomustine is being investigated in patients with grade 3 IDH mutant astrocytoma.

                            Product Name : DFMO

                            Product Type : Other Small Molecule

                            Upfront Cash : Inapplicable

                            November 22, 2024

                            Lead Product(s) : Eflornithine Hydrochloride,Lomustine

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase III

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Philogen

                            Italy arrow
                            AACR Annual meeting
                            Not Confirmed

                            Philogen

                            Italy arrow
                            AACR Annual meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Fibromun,Lomustine

                            Therapeutic Area : Oncology

                            Study Phase : Phase I/ Phase II

                            Sponsor : University Hospital Zürich

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Philogen Publishes New Data on A Fibromun-Based Treatment Combination in Science Translational Medicine in Col...

                            Details : L19TNF is a fully-human immunomodulatory product consisting of the L19 antibody and TNF. The L19 antibody is specific to the EDB domain of fibronectin and mediates selective localization of TNF to the site of disease while sparing healthy organs.

                            Product Name : L19TNF

                            Product Type : Protein

                            Upfront Cash : Inapplicable

                            May 24, 2023

                            Lead Product(s) : Fibromun,Lomustine

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I/ Phase II

                            Sponsor : University Hospital Zürich

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Biodexa Pharmaceuticals

                            United Kingdom arrow
                            AACR Annual meeting
                            Not Confirmed

                            Biodexa Pharmaceuticals

                            United Kingdom arrow
                            AACR Annual meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Panobinostat lactate,Lomustine

                            Therapeutic Area : Oncology

                            Study Phase : Phase I

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Biodexa Completes Recruitment of Cohort A in Study of MTX110 in Patients with Recurrent Glioblastoma

                            Details : MTX110 (panobinostat) is a hydroxamic acid and acts as a non-selective histone deacetylase inhibitor (pan-HDAC inhibitor), which is investigated for the treatment of patients with recurrent glioblastoma (rGBM).

                            Product Name : MTX110

                            Product Type : Other Small Molecule

                            Upfront Cash : Inapplicable

                            March 10, 2023

                            Lead Product(s) : Panobinostat lactate,Lomustine

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            Midatech Pharma

                            United Kingdom arrow
                            AACR Annual meeting
                            Not Confirmed

                            Midatech Pharma

                            United Kingdom arrow
                            AACR Annual meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Panobinostat lactate,Lomustine

                            Therapeutic Area : Oncology

                            Study Phase : Phase I

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            First Patient Enrolled in Phase 1 Study of MTX-110 (MAGIC-G1 Study) in Patients with Recurrent Glioblastoma

                            Details : MTX110 is a water-soluble form of panobinostat free base, achieved through complexation with hydroxypropyl-β-cyclodextrin (HPBCD), that enables convection-enhanced delivery (CED) at potentially chemotherapeutic doses directly to the site of the tumour.

                            Product Name : MTX110

                            Product Type : Other Small Molecule

                            Upfront Cash : Inapplicable

                            November 14, 2022

                            Lead Product(s) : Panobinostat lactate,Lomustine

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            Orbus Therapeutics

                            U.S.A arrow
                            AACR Annual meeting
                            Not Confirmed

                            Orbus Therapeutics

                            U.S.A arrow
                            AACR Annual meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Eflornithine Hydrochloride,Lomustine

                            Therapeutic Area : Oncology

                            Study Phase : Phase III

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Orbus Therapeutics’ Phase 3 Eflornithine STELLAR Study Reaches Full Patient Enrollment

                            Details : Enrollment of patients in Phase 3 STELLAR trial for DFMO (eflornithine hydrochloride), a novel cytostatic agent that irreversibly inhibits ornithine decarboxylase in patients in patients with recurrent anaplastic astrocytoma.

                            Product Name : DFMO

                            Product Type : Other Small Molecule

                            Upfront Cash : Inapplicable

                            January 19, 2022

                            Lead Product(s) : Eflornithine Hydrochloride,Lomustine

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase III

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            06

                            Orbus Therapeutics

                            U.S.A arrow
                            AACR Annual meeting
                            Not Confirmed

                            Orbus Therapeutics

                            U.S.A arrow
                            AACR Annual meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Eflornithine Hydrochloride,Lomustine

                            Therapeutic Area : Oncology

                            Study Phase : Phase III

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Orbus Therapeutics Granted European Patent for Method of Use for Eflornithine

                            Details : Eflornithine is a novel cytostatic agent that irreversibly inhibits ornithine decarboxylase, a key enzyme in mammalian polyamine biosynthesis that is up-regulated in certain types of cancer.

                            Product Name : DFMO

                            Product Type : Other Small Molecule

                            Upfront Cash : Inapplicable

                            September 28, 2021

                            Lead Product(s) : Eflornithine Hydrochloride,Lomustine

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase III

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            07

                            Orbus Therapeutics

                            U.S.A arrow
                            AACR Annual meeting
                            Not Confirmed

                            Orbus Therapeutics

                            U.S.A arrow
                            AACR Annual meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Eflornithine Hydrochloride,Lomustine

                            Therapeutic Area : Oncology

                            Study Phase : Phase III

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Orbus Therapeutics Receives U.S. Patent for Eflornithine Formulations

                            Details : Patent relates to a solution of eflornithine for oral administration currently being evaluated in Orbus’ Phase 3 STELLAR study in rare brain cancer.

                            Product Name : DFMO

                            Product Type : Other Small Molecule

                            Upfront Cash : Inapplicable

                            December 23, 2020

                            Lead Product(s) : Eflornithine Hydrochloride,Lomustine

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase III

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            08

                            Orbus Therapeutics

                            U.S.A arrow
                            AACR Annual meeting
                            Not Confirmed

                            Orbus Therapeutics

                            U.S.A arrow
                            AACR Annual meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Eflornithine Hydrochloride,Lomustine

                            Therapeutic Area : Oncology

                            Study Phase : Phase III

                            Sponsor : Longitude Capital

                            Deal Size : $71.0 million

                            Deal Type : Series A Financing

                            DEALS_DEV arrow-down

                            Orbus Therapeutics Expands Series A Financing to $71 Million to Support Ongoing STELLAR Phase 3 Study in Rare ...

                            Details : The expanded Series A funding will support the ongoing STELLAR study, a Phase 3 clinical trial studying eflornithine in patients with anaplastic astrocytoma whose cancer has recurred following radiation and adjuvant chemotherapy.

                            Product Name : DFMO

                            Product Type : Other Small Molecule

                            Upfront Cash : Undisclosed

                            October 22, 2020

                            Lead Product(s) : Eflornithine Hydrochloride,Lomustine

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase III

                            Sponsor : Longitude Capital

                            Deal Size : $71.0 million

                            Deal Type : Series A Financing

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth